GSK plc

GSK· NYSE· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$51.52-0.33%

2026-08-03

Financials

Valuation Metrics

GSK plc's Market Cap is $103.38B. At end of 2025 it was $99.07B. Ranked #152 of 3,112 in US market (top 5%), #105 of 1,667 on NYSE (top 6%), #13 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 5%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$103.38B	US#152/3,112 Sec#13/269
Revenue	$43.30B	US#161/3,112 Sec#11/269
Net Income	$7.70B	US#97/3,112 Sec#11/269
Total Assets	$111.55B	US#165/3,112 Sec#9/269
Net Assets	$31.68B	US#155/3,112 Sec#9/269
Value
P/E	13.43x	US#548/3,112 Sec#21/269
P/B	3.26x	US#1,777/3,112 Sec#98/269
PEG	1.93x	US#1,033/3,112 Sec#36/269
P/S	2.39x	US#1,455/3,112 Sec#40/269
EV/EBITDA	8.80x	US#590/3,112 Sec#23/269
FCF Yield	7.97%	US#742/3,112 Sec#27/269
Profitability
ROE	24.31%	US#420/3,112 Sec#30/269
ROA	6.90%	US#751/3,112 Sec#43/269
Op. Margin	25.67%	US#625/3,112 Sec#31/269
Revenue Growth	1.50%	US#2,102/3,112 Sec#121/269
Earnings Growth	6.96%	US#1,222/3,112 Sec#40/269
Financial Health
Debt Ratio	254.58%	US#1,995/3,112 Sec#210/269
Total Debt	$33.81B	US#139/3,112 Sec#10/269
FCF	$8.24B	US#98/3,112 Sec#10/269
Cash	$6.11B	US#166/3,112 Sec#9/269
Current Ratio	0.79x	US#2,501/3,112 Sec#269/269
Net Debt/EBITDA	1.86x	US#1,332/3,112 Sec#60/269
Dividend
Div. Yield	3.62%	US#443/3,112 Sec#6/269
Div. Growth	2.61%	US#1,009/3,112 Sec#17/269
Performance
1Y Return	37.17%	US#1,008/3,112 Sec#134/269
1M Return	-3.99%	US#2,140/3,112 Sec#117/269
From 52W High	-16.50%	US#1,504/3,112 Sec#88/269
1Y MDD	-19.91%	US#675/3,112 Sec#23/269
Trading
Volume	4,314,974 shares	US#434/3,112 Sec#34/269
Trading Value	$223M	US#484/3,112 Sec#25/269
Per Share
EPS	$3.68	US#840/3,112 Sec#23/269
BPS	$10.51	US#1,746/3,112 Sec#60/269